Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA. The biotech focuses on trawling the ...
Using CRISPR technology that targets RNA instead of DNA, researchers at New York University and the New York Genome Center searched across the genome and found nearly 800 noncoding RNAs important ...
Using CRISPR technology that targets RNA instead of DNA, researchers at New York University and the New York Genome Center searched across the genome and found nearly 800 noncoding RNAs important ...